SDAI (SGX:5TI) obtained an approval from China's National Medical Products Administration to sell its skincare line, Bluecode Biotech B-III series, according to a filing with the Singapore Exchange on Wednesday.
The approved series includes the Apple Fruit Cell Serum and the Adnium Obesum Cell Facial Mask.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.